Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Drugs in capsules, DNA and medicine, 3d rendering - Illustration
Payers see value in gene therapies, but capacity for mutiple products is limited. • Source: Shutterstock

Engaging with payers early and often about potential payment models for cell and gene therapies has given drug developers reason to be optimistic about pricing and reimbursement, but they acknowledge many challenges are ongoing when it comes to covering the cost of high-cost, high-impact medicines.

Both manufacturers and payers noted the progress and remaining struggles during panel discussions and in interviews during the Cell and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Drug Pricing

More from Scrip

Stock Watch: Q2 Sales Growth Sparks Diverging Reactions To J&J And Novartis

 
• By 

With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By 

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II

 

Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.